Loading stock data…
Prelude Therapeutics Incorporat (PRLD)
$4.93+0.55 (+12.56%)
After Hours$4.90-0.03 (-0.61%)· Last close Jun 29
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prelude Therapeutics Incorporated in the Healthcare sector is trading at $4.93 with a market capitalization of $344M. Wall Street consensus targets $8.00 (3 analysts), implying a +62.3% move over the next 12 months. The stock is currently near its 52-week high of $5.54, remaining 79.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +62.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.58M↓ | $5.64M↓ | $6.50M | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.18M↑ | -$17.35M↑ | -$20.42M↑ | -$32.19M↑ | -$34.61M |
| Net Income | -$10.38M↑ | -$16.46M↑ | -$19.73M↑ | -$31.23M↑ | -$32.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$344.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-129.27%
Volume
Today's trading volume
471,086
Recent News
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with an Early-Stage Biotech rating. Johnson said the company’s “differentiated approach” in metastatic breast cancer could unlock a $10B opportunity. On May 12, […]
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Last week, you might have seen that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) released its quarterly result to...
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer
Prelude Therapeutics (NASDAQ:PRLD) is one of the best biotech penny stocks to buy in 2026. On April 20, Prelude Therapeutics presented promising preclinical data for PRT13722, a first-in-class, oral KAT6A degrader. Designed for HR+/HER2- breast cancer, the candidate demonstrated the ability to achieve complete tumor regressions as a monotherapy across multiple models, including those resistant […]
Myriad Genetics And 2 Other Penny Stocks To Watch Closely
The United States market has shown robust growth, rising 3.5% over the last week and 31% over the past year, with earnings expected to increase by 16% annually in the coming years. In such a thriving market, identifying stocks with strong financials becomes crucial for investors seeking both affordability and growth potential. Although often considered a term from bygone eras, penny stocks continue to offer intriguing opportunities within smaller or newer companies that might surprise...